JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 6, 2005; DOI: 10.1124/jpet.104.076927


0022-3565/05/3142-818-824$20.00
JPET 314:818-824, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.076927v1
314/2/818    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, J.
Right arrow Articles by Quilley, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, J.
Right arrow Articles by Quilley, J.

CARDIOVASCULAR

Effect of Tempol on Renal Cyclooxygenase Expression and Activity in Experimental Diabetes in the Rat

Jing Li, Yu-Jung Chen, and John Quilley

Department of Pharmacology, New York Medical College, Valhalla, New York

Renal cyclooxygenase (COX)-2 expression is increased in the streptozotocin (STZ)-diabetic rat and is associated with enhanced renal prostaglandin release in response to arachidonic acid (AA). Endoperoxide-mediated vasoconstrictor responses to AA were also enhanced in the diabetic rat kidney. Because oxidative stress is increased in diabetes and has been shown to induce COX-2, we assessed its contribution to prostaglandin release by treating diabetic rats with tempol (120 mg/kg/day) for 28 days. Release of AA-stimulated prostaglandins PGE2 and 6-ketoPGF1{alpha} from the isolated perfused kidney was used as an index of COX activity, and Western analysis was used to determine COX-2 protein expression. In untreated diabetic rats, the release of prostaglandins in response to AA was markedly enhanced; the increase in release of both 6-ketoPGF1{alpha} and PGE2 after AA was twice that in control rats. Renal cortical COX-2 expression in diabetic rats was 3-fold that of control rats. Tempol treatment reduced the AA-stimulated release of prostaglandins to levels seen in control rats; this was associated with reduced expression of COX-2 protein to levels not different from that in control rats. However, the enhanced vasoconstrictor response to AA in diabetic rats was unaffected by tempol treatment but abolished by inhibition of COX-1 with SC58560 [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole]. The addition of tempol to the perfusate of kidneys from diabetic and control rats had only a slight effect on prostaglandin release. We conclude that oxidative stress is an integral component of the mechanism involved in the induction of renal COX-2 in diabetes.


Received August 31, 2004; accepted May 5, 2005.

Address correspondence to: Dr. John Quilley, Department of Pharmacology, New York Medical College, Valhalla, NY 10595. E-mail: john_quilley{at}nymc.edu




This article has been cited by other articles:


Home page
HypertensionHome page
A. Virdis, R. Colucci, D. Versari, N. Ghisu, M. Fornai, L. Antonioli, E. Duranti, E. Daghini, C. Giannarelli, C. Blandizzi, et al.
Atorvastatin Prevents Endothelial Dysfunction in Mesenteric Arteries From Spontaneously Hypertensive Rats: Role of Cyclooxygenase 2-Derived Contracting Prostanoids
Hypertension, June 1, 2009; 53(6): 1008 - 1016.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Araujo and W. J. Welch
Cyclooxygenase 2 inhibition suppresses tubuloglomerular feedback: roles of thromboxane receptors and nitric oxide
Am J Physiol Renal Physiol, April 1, 2009; 296(4): F790 - F794.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
C. S. Wilcox and A. Pearlman
Chemistry and Antihypertensive Effects of Tempol and Other Nitroxides
Pharmacol. Rev., December 1, 2008; 60(4): 418 - 469.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y.-J. Chen, J. Li, and J. Quilley
Deficient renal 20-HETE release in the diabetic rat is not the result of oxidative stress
Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2305 - H2312.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y.-J. Chen and J. Quilley
Fenofibrate Treatment of Diabetic Rats Reduces Nitrosative Stress, Renal Cyclooxygenase-2 Expression, and Enhanced Renal Prostaglandin Release
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 658 - 663.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
E. A. Jaimes, M.-S. Zhou, D. D. Pearse, L. Puzis, and L. Raij
Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species
Am J Physiol Renal Physiol, February 1, 2008; 294(2): F385 - F392.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Alvarez, J. V. Perez-Giron, R. Hernanz, A. M. Briones, A. Garcia-Redondo, A. Beltran, M. J. Alonso, and M. Salaices
Losartan Reduces the Increased Participation of Cyclooxygenase-2-Derived Products in Vascular Responses of Hypertensive Rats
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 381 - 388.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Guo, Z. Xia, J. Jiang, and J. H. McNeill
Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1728 - H1736.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.